Skip to main content

Advertisement

Table 6 Univariate analysis of the association of treatment system -related characteristics with an unfavourable outcome in 231 cases treated for at least 24 hours

From: Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study

Variable Total Death Other unfavourable All unfavourable (death and other) together
   N N OR (95% CI) p N OR (95% CI) p N OR (95% CI) p
Specialty responsible for starting treatment pulmonary 185 18 1   34 1   52 1  
  internal medicine 33 9 3.50 (1.38-8.90) 0.009 5 1.02 (0.36-2.96) 0.96 14 0.43 (0.06-2.97) 0.39
  general medicine 2 2 Inf³ 1.00 0 1.05 1.00 2 0.23 (0.04-1.20) 0.08
  other 11 3 4.43 (0.98-20.14) 0.05 3 2.35 (0.53-10.31) 0.26 6 0.61 (0.12-2.10) 0.37
Specialty responsible for ending treatment pulmonary 161 8 1   34 1   42 1  
  internal medicine 29 7 6.13 (1.97-19.05) 0.002 5 1.03 (0.35-2.99) 0.96 12 2.00 (0.88-4.53) 0.10
  general medicine 35 16 14.00 (5.21-37.65) <0.001 2 0.41 (0.09-1.87) 0.25 18 3.00 (1.42-6.35) 0.004
  other 6 1 3.72 (0.37-37.29) 0.26 1 0.41 (0.09-8.09) 0.91 2 1.42 (0.25-8.02) 0.69
Change of specialty responsible for treatment no 174 16 1   32 1   48 1  
  yes 57 16 4.06 (1.83-9.02) 0.001 10 1.27 (0.56-2.86) 0.58 26 2.20 (1.19-4.09) 0.01
Number of cases per year for unit responsible for ending treatment 1 - 4 55 16 4.37 (1.86-10.28) 0.001 10 1.49 (0.63-3.50) 0.36 26 2.51 (1.30-4.84) 0.006
  5 - 10 12 1 0.88 (0.10-7.56) 0.91 2 0.96 (0.19-4.76) 0.96 3 0.93 (0.24-3.64) 0.92
  11 - 29 34 3 1.03 (0.27-3.96) 0.96 8 1.50 (0.59-3.80) 0.39 11 1.34 (0.59-3.03) 0.49
  30 - 129 12 1   22 1   34 1  
Treatment group standard treatment A 132 18 1   17 1   35 1  
  standard treatment B 24 5 2.69 (0.82-8.82) 0.10 9 5.14 (1.82-14.49) 0.002 14 3.88 (1.58-9.53) 0.003
  standard treatment C 17 1 0.40 (0.05-3.11) 0.37 2 0.82 (0.17-3.91) 0.80 3 0.59 (0.16-2.19) 0.43
  standard treatment D 19 1 0.41 (0.05-3.37) 0.41 5 2.19 (0.69-6.95) 0.18 6 1.28 (0.45-3.62) 0.64
  other combination 34 6 1.70 (0.60-4.84) 0.32 9 2.70 (1.05-6.96) 0.04 15 2.19 (1.00-4.77) 0.049
  ineffective 5 1 1.35 (0.14-12.76) 0.80 0 0 1.00 1 0.69 (0.07-6.41) 0.74
Change in treatment group no 159 22 1   22 1   44 1  
  yes 72 10 1.00 (0.43-2.34) 0.99 20 2.12 (1.05-4.27) 0.04 30 1.56 (0.87-2.80) 0.13
Pause of treatment no 169 25 1   22 1   47 1  
  yes 62 7 0.98 (0.39-2.45) 0.96 20 3.17 (1.55-6.46) 0.002 27 2.00 (1.09-3.66) 0.02
Pause during intensive phase¹ no 183 25 1   24 1   49 1  
  yes 47 6 1.40 (0.52-3.78) 0.51 18 4.37 (2.05-9.29) <0.001 24 2.88 (1.43-5.78) 0.003
Pause during intensive phase, due to side effect no 191 26 1   27 1   53 1  
  yes 40 6 1.68 (0.61-4.60) 0.32 15 4.04 (1.82-8.92) 0.001 21 2.85 (1.48-5.51) 0.002
Pause during continuation phase no 171 12 1   25 1   37 1  
  yes 34 2 1.12 (0.23-5.36) 0.89 12 3.22 (1.40-7.40) 0.006 14 2.53 (1.17-5.50) 0.02
  NA (other + ineffective) 26 18    5    23   
Total   231 32    42    74   
  1. Significant p-values are darkened.
  2. ¹ Information missing for one case
  3. ² Information missing for 3 cases
  4. ³ Max likelihood estimate is not finite.